Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Breast 2Genitourinary 1

Conditions

Endometrial Neoplasms 2Breast Neoplasms 2Prostatic Neoplasms 1

Interventions

pembrolizumab 1024Carboplatin 966Paclitaxel 933Gemcitabine 794Cisplatin 753Docetaxel 684Bevacizumab 609Pemetrexed 504Nivolumab 487Cyclophosphamide 474Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 373Oxaliplatin 348Injections 347atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 246Doxorubicin 241Ipilimumab 226fludarabine 220Lenalidomide 220Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × irosustat × Clear all
NCT01840488 2019-11-22

BN83495 Phase I in Post-menopausal Women

Ipsen

Phase 1 Completed
50 enrolled
Breast

Breast Neoplasms

NCT00910091 2019-01-30

The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer

Ipsen

Phase 2 Completed
73 enrolled 19 charts
Gynecologic

Endometrial Neoplasms

NCT00790374 2019-01-15

STX64PC

Ipsen

Phase 1 Completed
17 enrolled
Genitourinary

Prostatic Neoplasms

NCT01251354 2019-01-14

Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy

Ipsen

Phase 2 Terminated
6 enrolled 7 charts
Gynecologic

Endometrial Neoplasms

NCT01230970 2019-01-07

Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer

Ipsen

Phase 2 Terminated
2 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡